Retail wanted EMJX but SRX Global is the better trade. Here's why
Let me start with the obvious. A lot of people are unhappy with the news. The expectation was clean: EMJX merger closes, ticker becomes EMJX, retail rides the crypto treasury narrative, simple play.
What we got instead is SRX Global with EMJX as a subsidiary, Eric as President of EMJX and Head of Asset Management rather than parent CEO, and a board that retail doesn't recognize. The brand reveal was anticlimactic. The selling pressure on thursday reflects that disappointment.
I get it. The simple version was easier to hold. However the structure we actually got is the better trade.
EMJX standalone would have been additive. SRX Global is multiplicative.
A clean EMJX reverse merger would have given retail what they wanted: one brand, one ticker, one thesis. Eric runs it, the algorithmic engine performs, the treasury compounds, retail prices it as a crypto treasury play. Ceiling is bounded by how good the EMJX engine is in isolation.
SRX Global is a platform. EMJX is one subsidiary inside it. The board around Eric is a team that was assembled in stages through 2025 specifically for the kind of pivot he was going to bring. Eric's engine, Dorf's DAT playbook, the capital markets bench, and future IP drops all compound together. That's a different scaling curve.
The board refresh was sequenced. The following timing tells you everything.
- October 1, 2025: Joshua Epstein joins the board. 20+ years across energy, technology, healthcare, medical cannabis, blockchain, and gaming. Former CEO of Socati Corp, former President and COO of Nuuvera (cannabis company acquired by Tilray for $826M in 2018), former Partner at FastForward Innovations. JD from University of Texas (Texas Law Review), MBA from Acton (valedictorian). M&A attorney background at Baker Botts before going operational.
- October 31, 2025: Lionel Conacher and David White resign from the board. This is the cleanup. Conacher had been Chairman through the SRx Canada era. His departure removes the legacy positioning and clears the way for the digital asset pivot.
- November 10, 2025: Sammy Dorf joins the board. Co-founder of Verano Holdings, scaled to 120+ dispensaries in 13 states, $925M+ revenue. Former Executive Chairman of Flora Growth Corp (NASDAQ: FLGC), where he guided the company's transition into a crypto treasury company in late 2024 / early 2025. Direct experience with the exact playbook EMJX is now executing.
- December 16, 2025: EMJX merger announced. Five weeks after Dorf joined.
The board was being rebuilt for a deal like EMJX. Then the deal arrived. That's deliberate sequencing.
Eric got a Gen2 DAT execution team.
- Sammy Dorf is the piece nobody is pricing in. He oversaw Flora Growth's transition into a crypto treasury company, which is the most recent and most directly comparable playbook to what EMJX is doing. Eric doesn't have to invent the structure. Dorf has built it before publicly.
- Michael Young is the largest individual shareholder (23.93% as of October 2025) and was the board member through whom Eric was introduced to the company. The S-4 makes the sequencing explicit: after SRx Canada was wound down, the board considered uranium royalties and oil and gas businesses, and then Young was introduced to Jackson. That introduction led to the EMJX acquisition. Young is the deal sourcer. He sits on the post-closing board because he's the architect of this third pivot. Young may be also connected to the Keystone ELOC deal.
- Simon Conway is a Chartered Accountant (BDO) and co-founded Matterhorn Capital, which has transacted £1.5B+ across the UK, France, Bermuda, St Lucia, and the US. He chairs the Audit Committee. Real estate, debt structuring, and capital raising expertise during a period of major capital structure changes.
- Joshua Epstein brings the blockchain, M&A, and securities law background. Cross-sector deal experience across energy, tech, healthcare, cannabis, and blockchain. JD plus MBA plus operational CEO experience. The kind of director who can navigate the regulatory and transactional complexity of building out the platform.
This is a deliberately assembled team with the right mix of DAT execution, capital markets, financial structure, and dealmaking depth.
What Eric saw that retail is missing, the shell wasn't junk. It was a re-built launching pad with:
- A board specifically refreshed for the pivot he wanted to execute
- Direct DAT execution experience already on the board through Dorf
- Capital markets relationships
- Operational continuity for the legacy business via Cunningham as parent CEO
- Massive financing capacity already operational through the $1B Keystone ELOC
- NYSE American listing maintained
- A documented willingness from the board to back transformational deals
Jackson is stepping into a vehicle that was already being prepared for someone like him.
Why the platform structure compounds.
If Eric had pursued EMJX as a standalone IPO or SPAC:
- 12-18 months of regulatory friction
- Significant cash burn during listing
- No operational team built yet
- No existing capital markets relationships
- One brand, one vertical, ceiling defined by the engine alone
What he got instead:
- Operational from day one
- Existing institutional infrastructure
- A board with proven DAT execution experience alongside him
- Multi-vertical platform structure (EMJX, future IP drops, legacy cash flow)
- $1B ELOC accessible immediately Saylor-class platform compounding model
The parent is the platform. EMJX is the first operating engine. EventHorizonIQ and TonalityIQ are the IP drops to follow. Additional verticals can be added without rebranding.
And this is the part most retail commentary gets wrong. The pet food and pharmacy failures aren't part of SRX Global's go-forward business.
- Better Choice (pet food era, through April 2025): Persistent losses, 1-for-44 reverse split executed March 20, 2024 to maintain NYSE compliance. Sub-scale operation. The current board mostly wasn't there.
- SRx Health Solutions Canada (April 2025 to August 2025): $125M acquisition closed April 24, 2025. Canadian specialty pharmacy. Filed for CCAA bankruptcy protection on August 11, 2025. Operations classified as discontinued.
- Settlement Agreement (August 14, 2025): 18.8M shares forfeited from the SRx founders, representing roughly 46% of fully diluted shares. The company actively clawed equity back from the failed pivot before resetting.
- SRX Global (June 18, 2026 onward): Halo pet food remains as a small residual legacy asset (about $6.5M). The Canadian pharmacy operations are gone. The new core business is the EMJX digital asset treasury platform plus the IP carve-out drops to follow.
Accountability map of the current board:
- Young: On the board throughout, governance role, never operated either failed business
- Conway: Joined April 24, 2025 with the SRx merger, the pharmacy was Vora's operational responsibility
- Epstein: Joined October 1, 2025, after the failure was contained
- Dorf: Joined November 10, 2025, well after the cleanup
None of the current board members operated either of the failed businesses. They inherited or joined post-cleanup.
Bottom line for position sizing.
Thursday's selling is sell-the-news plus brand expectation mismatch. The price action reflects that retail didn't get the simple EMJX ticker they were positioned for.
The structural reality is that SRX Global is a stronger starting position than standalone EMJX would have been. Right board, right infrastructure, right financing capacity, right time. The failed businesses are contained. The current team isn't accountable for them. Eric stepped into a vehicle that was being prepared for an operator like him.
Execution risk is real and entirely about Eric and Dorf delivering on the Gen2 DAT thesis. The structural setup is stronger than the retail narrative suggests.
The opportunity is structured differently than retail expected.
Sources:
SRX Global press release (June 18, 2026 closing): https://www.globenewswire.com/news-release/2026/06/18/3314161/0/en/srx-health-solutions-closes-emjx-acquisition-and-launches-ai-driven-platform-strategy-under-new-name-and-brand-srx-global-focused-on-investments-in-high-conviction-operating-compan.html
SRX Global governance page: https://www.srxglobalinc.com/governance
Sammy Dorf appointment 8-K (November 10, 2025): https://www.stocktitan.net/sec-filings/SRXH/8-k-s-rx-health-solutions-inc-reports-material-event-88f97e8c612d.html
Form S-4 (April 14, 2026): https://www.sec.gov/Archives/edgar/data/1471727/000149315226016588/forms-4.htm
SRx Health Solutions shareholder consent (December 23, 2025): https://www.sec.gov/Archives/edgar/data/1471727/000149315225028965/form8-k.htm
Flora Growth Sammy Dorf appointment (December 10, 2024): https://www.newsfilecorp.com/release/233101/Flora-Growth-Appoints-Sammy-Dorf-Verano-CoFounder-as-Executive-Chairman
Better Choice / SRx Health acquisition announcement (September 3, 2024): https://www.globenewswire.com/news-release/2024/09/03/2939709/0/en/Better-Choice-Company-Signs-Definitive-Agreement-to-Acquire-SRx-Health-for-Approximately-125-Million.html
SRX Global Q2 FY26 10-Q: https://www.stocktitan.net/sec-filings/SRXH/10-q-s-rx-health-solutions-inc-quarterly-earnings-report-9d8f552bc7ba.html